US Health Regulators Will Approve Generic Versions of OxyContin Only If It Comes With Anti-Abuse Properties

by Kathy Jones on April 19, 2013 at 9:36 PM
 US Health Regulators Will Approve Generic Versions of OxyContin Only If It Comes With Anti-Abuse Properties

American health regulators revealed that they will not be approving any generic forms of OxyContin unless they come with abuse-curbing properties of a reformulated version of the painkiller drug.

Manufacturer Perdue Pharma discontinued original OxyContin (oxycodone hydrochloride) in 2010 after the US Food and Drug Administration approved a new version of the drug that is more difficult to snort or inject.


"Because original OxyContin provides the same therapeutic benefits as reformulated OxyContin, but poses an increased potential for certain types of abuse, the FDA has determined that the benefits of original OxyContin no longer outweigh its risks," the FDA said in a statement late Tuesday.

"Accordingly, the agency will not accept or approve any abbreviated new drug applications (generics) that rely upon the approval of original OxyContin."

FDA Deputy Director Douglas Throckmorton said that "while both original and reformulated OxyContin are subject to abuse and misuse," reformulated OxyContin is more difficult to crush or melt down, making it harder to snort or inject.

"When FDA finds that a new formulation has abuse deterrent properties, the agency has the authority to require generics to have abuse-deterrent properties also," regulators said, indicating the ruling could apply to other medicines.

OxyContin sales generated $2.8 billion in 2012, according to IMS Health, an industry information service. The latest FDA ruling extends Perdue Pharma's patent protection over the drug.

The original version of the drug was designed to dissolve slowly, without giving users the feeling of euphoria that leads to addiction. But addicts found they could surmount the safeguard by snorting or injecting the drug.

OxyContin shot to popularity in the last decade, largely in rural parts of the United States, gaining the nickname "Hillbilly Heroin."

The changes to the drug appear to have curbed addiction however, and a July 2012 study in the New England Journal of Medicine found that users were switching to heroin and other dangerous street drugs that give a similar high.

Source: AFP
Font : A-A+



Recommended Readings

Latest Drug News

Prolonging Market Exclusivity of Brand-name Insulin
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
FDA Boosts Orphan Drug Designations for Myelofibrosis Treatments
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
Anti-Rheumatic Drugs May Help Prevent Thyroid Disease
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Apotransferrin's Potential in Early Stroke Therapy Revealed
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.
Anti-cancer Drug Navitoclax Help Treat Lower Back Pain
The reduction of these senescent osteoclasts, possibly through the utilization of current medications, could present a novel approach in managing lower back pain.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

US Health Regulators Will Approve Generic Versions of OxyContin Only If It Comes With Anti-Abuse Properties Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests